Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cirtuvivint - Biosplice Therapeutics

Next Previous
Drug Profile

Cirtuvivint - Biosplice Therapeutics

Alternative Names: NSC-835563; SM-08502

Latest Information Update: 12 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samumed
  • Developer Biosplice Therapeutics
  • Class Amides; Antineoplastics; Isoquinolines; Piperazines; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action DYRK kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Soft tissue sarcoma
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
  • Preclinical Haematological malignancies
  • No development reported Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 09 Sep 2025 Phase-II clinical trials in Soft tissue sarcoma (Late-stage disease) (PO) (NCT05633307)
  • 04 Sep 2025 Biosplice Therapeutics plans a phase I/II (SLICK) trial for Small cell lung cancer (Second line therapy or greater, Combination therapy) in USA (PO) (NCT07155200)
  • 28 Jul 2025 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top